The global Biologics Safety Testing Market is experiencing rapid growth as the biopharmaceutical industry accelerates the development of advanced therapeutics, including cell and gene therapies, monoclonal antibodies, vaccines, and biosimilars. According to MarketsandMarkets™, the market is projected to grow from USD 5.57 billion in 2026 to USD 9.66 billion by 2031, registering a robust CAGR of 11.6% during the forecast period.
The increasing complexity of biologics, evolving regulatory frameworks, and rising outsourcing activities across the biopharmaceutical value chain are significantly driving demand for comprehensive safety testing solutions worldwide.
Access Comprehensive Market Intelligence
Explore detailed market insights, growth opportunities, competitive analysis, and future trends in the complete report.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144
Biologics Safety Testing Market Snapshot
- Market Size (2026): USD 5.57 Billion
- Projected Market Size (2031): USD 9.66 Billion
- CAGR (2026–2031): 11.6%
- Largest End User Segment: Pharmaceutical & Biotechnology Companies (56.0% market share in 2025)
- Largest Regional Market: North America (43.0% market share in 2025)
- Fastest-Growing Application Segment: Vaccine Safety Testing
Rising Adoption of Advanced Therapies Accelerating Market Growth
The rapid advancement of innovative biologic modalities, particularly cell therapies, gene therapies, and mRNA-based products, is transforming the healthcare landscape and creating unprecedented demand for biologics safety testing.
These advanced therapeutic platforms require rigorous testing to ensure:
- Product purity and potency
- Viral safety
- Sterility assurance
- Absence of adventitious agents
- Batch-to-batch consistency
- Regulatory compliance
As the global pipeline of biologics and biosimilars continues to expand, manufacturers are increasingly investing in sophisticated safety testing strategies to support product approvals and commercialization.
Services Segment Leads the Global Market
Based on offerings, the services segment accounted for the largest share of the biologics safety testing market in 2025.
The segment’s leadership is primarily driven by growing outsourcing activities among biopharmaceutical companies seeking specialized expertise and cost efficiencies.
Several factors continue to support service segment growth:
- Increasing outsourcing to Contract Research Organizations (CROs)
- Growing reliance on Contract Development and Manufacturing Organizations (CDMOs)
- Rising complexity of biologics manufacturing
- Need for specialized testing capabilities
- Expanding regulatory requirements
- Demand for end-to-end quality assurance solutions
Biopharmaceutical companies are increasingly partnering with external service providers to access advanced analytical capabilities, accelerate development timelines, and optimize operational costs.
Vaccine Safety Testing Emerges as the Fastest-Growing Application Segment
Among service applications, vaccine safety testing is projected to register the highest growth during the forecast period.
Several factors are contributing to this rapid expansion:
- Increasing global immunization initiatives
- Growing vaccine manufacturing capacity
- Rising investments in next-generation vaccines
- Expansion of pandemic preparedness programs
- Stringent batch release requirements
- Continuous development of novel vaccine platforms
Regulatory agencies worldwide continue to enforce rigorous safety standards for vaccines, further strengthening demand for comprehensive testing services.
As vaccine innovation accelerates, manufacturers increasingly require advanced testing solutions to ensure product safety, efficacy, and quality.
Pharmaceutical & Biotechnology Companies Drive Market Demand
Pharmaceutical and biotechnology companies represented the largest end-user segment in 2025, accounting for 56.0% of the market share.
The growing biologics pipeline across therapeutic areas such as oncology, immunology, rare diseases, and infectious diseases is significantly increasing testing requirements.
Key factors supporting demand from this segment include:
- Expanding biologics R&D activities
- Increasing biosimilar development programs
- Growing clinical trial volumes
- Regulatory emphasis on product safety
- Rising commercialization of advanced therapies
As companies seek to accelerate innovation while maintaining compliance, investment in biologics safety testing continues to rise.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=34624144
North America Maintains Market Leadership
North America accounted for the largest regional share of the biologics safety testing market in 2025.
The region’s dominance is supported by several strategic advantages:
- Strong presence of leading biopharmaceutical companies
- Advanced research and manufacturing infrastructure
- Robust clinical trial ecosystem
- Stringent regulatory oversight from the FDA
- High adoption of innovative biologics
- Significant public and private funding
The United States remains a major hub for biologics innovation, supported by extensive outsourcing activities, strong academic-industry collaborations, and substantial investments in next-generation therapies.
Additionally, the increasing adoption of cell and gene therapies continues to strengthen demand for specialized safety testing services across North America.
Emerging Trends Reshaping the Market
Several technological and industry trends are expected to redefine biologics safety testing over the coming years:
Integration of Advanced Analytical Technologies
Innovative analytical platforms are improving detection sensitivity, throughput, and testing accuracy.
Growing Adoption of Automation
Automation is enhancing laboratory efficiency, reducing human error, and accelerating turnaround times.
Expansion of Rapid Microbiological Methods
Rapid testing technologies are enabling faster product release while maintaining stringent quality standards.
Increasing Use of Digital Quality Systems
Digitalization and data-driven quality management systems are improving traceability, compliance, and operational efficiency.
Rising Focus on Risk-Based Testing Approaches
Manufacturers are increasingly implementing risk-based quality strategies to optimize testing workflows and regulatory compliance.
Competitive Landscape
The biologics safety testing market features a highly competitive landscape characterized by strategic partnerships, acquisitions, technological innovation, and service expansion.
Leading companies operating in the market include:
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Lonza
- FUJIFILM Corporation
- Sartorius AG
- F. Hoffmann-La Roche Ltd.
- Charles River Laboratories
- bioMérieux
- Maravai LifeSciences
- WuXi AppTec
- SGS Société Générale de Surveillance SA
- Sotera Health
- Samsung Biologics
- GenScript
- Agilent Technologies, Inc.
- Syngene International Limited
- Eurofins Scientific
- Laboratory Corporation of America Holdings
- Bio-Rad Laboratories, Inc.
- QIAGEN
These organizations continue to invest in expanding service portfolios, strengthening global laboratory networks, and enhancing advanced testing capabilities to meet evolving industry demands.
Conclusion
The global biologics safety testing market is positioned for significant growth through 2031, fueled by the rapid expansion of biologics pipelines, increasing regulatory scrutiny, and the growing adoption of advanced therapeutic modalities.
As biopharmaceutical innovation accelerates, comprehensive safety testing will remain essential to ensuring product quality, patient safety, and regulatory compliance across the biologics lifecycle.
Organizations that invest in advanced testing capabilities, automation, and strategic outsourcing partnerships will be best positioned to capitalize on emerging opportunities in this dynamic market.
Inquire Before Buying:
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=34624144
